Recent litigation experts have determined that Sanofi-Aventis the maker of the chemotherapy drug Taxotere only began to warn patients about the risk of permanent Alopecia after the Food and Drug Administration (FDA) forced their hand. This is not only unacceptable, but unfathomable. Pharmaceutical companies must be transparent with patients about the potentially life-altering side effects of their drugs. Cancer patients have endured permanent Alopecia (hair loss) after being prescribed this drug with no advance warning that their hair loss would be permanent.
It was recently announced that the US Food and Drug Administration (FDA) will require warnings for gadolinium-based contrast agents (GBCAs). These warnings are enforced to alert patients of the potential harm caused by gadolinium retention. As of May 2018, healthcare providers that handle GBCAs were provided updated prescribing information for these contrast agents. Gadolinium is another harmful substance concealed by pharmaceutical companies, leading to patients sustaining life threatening organ failure.